Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9 (NCT07652203) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9
China466 participantsStarted 2026-06
Plain-language summary
Non selective beta blockers (NSBBs), such as propranolol and nadolol, are mainstay therapies for portal hypertension in cirrhosis, but their efficacy and safety vary depending on the stage of the disease. Emerging evidence suggests that NSBBs may worsen the prognosis of advanced cirrhosis, especially in patients with a model for end-stage liver disease (MELD) score of \>9. The purpose of this randomized controlled trial is to evaluate the effects of the use of propranolol as recommended by the guideline on the prognosis in cirrhotic patients with a MELD score of \>9.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* patients' age ≥18 years;
* patients with a definitive diagnosis of liver cirrhosis;
* patients with a MELD score of \>9;
* patients with a history of decompensation or those who are experiencing their first decompensation, such as ascites, variceal bleeding, or hepatic encephalopathy (HE);
* patients' informed consents.
Exclusion Criteria:
* patients without a definite indication for NSBBs;
* patients with an absolute contraindication of NSBBs (severe bronchospasm, asthma, severe psychosis, high-degree atrioventricular block, etc.);
* patients with hypersensitivity to NSBBs;
* patients who had been treated with NSBBs before 2 weeks of enrollment;
* patients with occlusive portal vein thrombosis;
* patients who had undergone liver transplantation;
* patients who had undergone transjugular intrahepatic portosystemic shunt (TIPS);
* patients with a definitive diagnosis of hepatocellular carcinoma;
* patients with an estimated life time of \<12 months due to the presence of any comorbidities;
* patients who are currently pregnant or breast-feeding.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The time from randomization to the occurrence of further decompensation
Timeframe: Time to first further decompensation event, assessed from randomization up to the end of the study (maximum of approximately 96 weeks)
Trial details
NCT IDNCT07652203
SponsorGeneral Hospital of Shenyang Military Region